Johnson & Johnson (NYSE:JNJ) today announced new results from the Phase 1b/2 OrigAMI-4 study showing that first-line treatment with investigational subcutaneous amivantamab and hyaluronidase-lpuj in ...
Janice Min, editor of The Ankler, offers an un-sunny assessment of the world's entertainment capital: "There is definitely a Detroit vibe underway." ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results